{"commentary":{"count":149,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":55,"youtube":53,"x_thread":41},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04484142\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04484142","nct_id":"NCT04484142","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04484142. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive 6.0 mg/kg of DS-1062a","label":"DS-1062a 6.0 mg/kg","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2026-02-04","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":137,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"DS-1062a","type":"DRUG"}],"last_update":"2026-03-24","lead_sponsor":"Daiichi Sankyo","official_title":"Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Platinum Based Chemotherapy (TROPION-Lung05)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-03-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR)","timeFrame":"From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months."}],"references":[{"citation":"Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, Pons-Tostivint E, Perol M, Felip E, Sugawara S, Hayashi H, Cho BC, Blumenschein G Jr, Shum E, Lee JS, Heist RS, Cornelissen R, Chang WC, Kowalski D, Zebger-Gong H, Chargualaf M, Gu W, Lan L, Howarth P, Joseph R, Okamoto I. A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC. J Thorac Oncol. 2025 Nov;20(11):1669-1682. doi: 10.1016/j.jtho.2025.06.002. Epub 2025 Jun 12.","pmid":"40516821","type":"DERIVED"},{"citation":"Sands J, Ahn MJ, Lisberg A, Cho BC, Blumenschein G Jr, Shum E, Pons Tostivint E, Goto Y, Yoh K, Heist R, Shimizu J, Lee JS, Baas P, Planchard D, Perol M, Felip E, Su WC, Zebger-Gong H, Lan L, Liu C, Howarth P, Chiaverelli R, Paz-Ares L. Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. J Clin Oncol. 2025 Apr;43(10):1254-1265. doi: 10.1200/JCO-24-01349. Epub 2025 Jan 6.","pmid":"39761483","type":"DERIVED"}],"start_date":{"date":"2021-03-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)","url":"https://clinicaltrials.gov/study/NCT04484142"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04484142"}